Pepdox
Studies
Peptides
Calculator
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes. | Pepdox
Home
/
Search
/
PMID 30845101
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
The Medical letter on drugs and therapeutics
2019
PMID: 30845101
View on PubMed
Semaglutide
Keywords
Adlyxin
Adlyxine
Bydureon
Farxiga
Forxiga
Glucophage
Invokana
Jardiance
Ozempic
Trulicity
Victoza
adverse effects
canagliflozin
dapagliflozin
dosage
dulaglutide
efficacy
empagliflozin
exenatide
liraglutide
lixisenatide
metformin
safety
semaglutide
type 2 diabetes